* Aridis Pharmaceuticals Inc ARDS.OQ ARDS.O is expected
to show a rise in quarterly revenue when it reports results on
August 10 (estimated).
* The Los Gatos California-based company is expected to
report a
31,604.5% increase in revenue to $10.463 million from $33
thousand a year ago, according to the mean estimate from 2
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Aridis
Pharmaceuticals
Inc is for a loss of 6 cents per share. For the same quarter
last year, the company reported a loss of 55 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Aridis
Pharmaceuticals Inc is $11.5, above its last closing price
of $2.24.
* Previous quarterly performance (using preferred earnings
measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2022 -0.51 -0.51 -0.44 Beat 13.7
Dec. 31 2022 -0.51 -0.41 -0.92 Missed -124.4
Sep. 30 2021 -0.51 -0.51 -1.94 Missed -277.9
Jun. 30 2021 -0.64 -0.63 -0.55 Beat 12.4
Mar. -0.61 -0.62 -0.77 Missed -24.7
31 2021
Dec. 31 2020 -0.59 -0.59 Met 0.6
Sep. 30 2020 -0.64 -0.63 -0.65 Missed -3.5
Jun. 30 2020 -0.74 -0.74 -0.47 Beat 36.8
This summary was machine generated August 8 at 15:10 GMT. All
figures in US dollars unless otherwise stated